Cargando…

Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß

Interferon beta (IFNß) is a common treatment used for multiple sclerosis (MS) which acts through the activation of the JAK-STAT pathway. However, this therapy is not always effective and currently there are no reliable biomarkers to predict therapeutic response. We postulate that the heterogeneity i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurtado-Guerrero, Isaac, Pinto-Medel, Maria Jesús, Urbaneja, Patricia, Rodriguez- Bada, Jose Luis, León, Antonio, Guerrero, Miguel, Fernández, Óscar, Leyva, Laura, Oliver-Martos, Begoña
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245989/ https://www.ncbi.nlm.nih.gov/pubmed/28103257 http://dx.doi.org/10.1371/journal.pone.0170031

Ejemplares similares

Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway
por: Hurtado-Guerrero, Isaac, et al.
Publicado: (2017)

Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
por: Pinto-Medel, María Jesús, et al.
Publicado: (2017)

Skin Phototype Could Be a Risk Factor for Multiple Sclerosis
por: Urbaneja, Patricia, et al.
Publicado: (2020)

TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
por: López-Gómez, Carlos, et al.
Publicado: (2016)

Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation
por: Hurtado-Guerrero, Isaac, et al.
Publicado: (2020)

Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment
por: Aliaga-Gaspar, Pablo, et al.
Publicado: (2021)

TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011)

Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations
por: Ciano-Petersen, Nicolás Lundahl, et al.
Publicado: (2023)

Candidate Gene Study of TRAIL and TRAIL Receptors: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients
por: López-Gómez, Carlos, et al.
Publicado: (2013)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

A JAK/STAT invasion
por: Wells, William A.
Publicado: (2002)

JAK-STAT and bone metabolism
por: Li, Jiliang
Publicado: (2013)

The Drosophila JAK-STAT pathway
por: Zeidler, Martin P, et al.
Publicado: (2013)

Evolution of the JAK-STAT pathway
por: Liongue, Clifford, et al.
Publicado: (2013)

The JAK-STAT pathway at 20
por: Darnell, Jr., James E.
Publicado: (2012)

JAK-STAT in lymphoproliferative disorders
por: Rabadan, Raul, et al.
Publicado: (2015)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Mesenchymal properties of SJL mice-stem cells and their efficacy as autologous therapy in a relapsing–remitting multiple sclerosis model
por: Marin-Bañasco, Carmen, et al.
Publicado: (2014)

JAK/STAT and Hox Dynamic Interactions in an Organogenetic Gene Cascade
por: Pinto, Pedro B., et al.
Publicado: (2015)

JAK-STAT in heterochromatin and genome stability
por: Silver-Morse, Louise, et al.
Publicado: (2013)

JAK-STAT and intestinal mucosal immunology
por: Heneghan, Aaron F, et al.
Publicado: (2013)

JAK-STAT: Getting to the heart of the matter
por: Barry, Sean P.
Publicado: (2012)

JAK-STAT pathway and myogenic differentiation
por: Jang, You-Na, et al.
Publicado: (2013)

JAK-STAT Signalling Pathway in Cancer
por: Brooks, Andrew J., et al.
Publicado: (2020)

JAK/STAT signaling in hepatocellular carcinoma
por: Hin Tang, Justin Jit, et al.
Publicado: (2020)

JAK-STAT in Early Hematopoiesis and Leukemia
por: Fasouli, Eirini Sofia, et al.
Publicado: (2021)

JAK-STAT pathway inhibitors in dermatology()
por: Miot, Hélio Amante, et al.
Publicado: (2023)

Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway
por: Au-Yeung, Nancy, et al.
Publicado: (2013)

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
por: Govaerts, Inge, et al.
Publicado: (2019)

Inhibition of JAK/STAT signaling stimulates adult satellite cell function
por: Price, Feodor D., et al.
Publicado: (2014)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris
por: Juczynska, K., et al.
Publicado: (2020)

The JAK/STAT Pathway Is Involved in Synaptic Plasticity
por: Nicolas, Céline S., et al.
Publicado: (2012)

JAK/STAT signaling and human in vitro myogenesis
por: Trenerry, Marissa K, et al.
Publicado: (2011)

JAK-STAT signaling and myocardial glucose metabolism
por: Frias, Miguel A, et al.
Publicado: (2013)

JAK-STAT3 and somatic cell reprogramming
por: Tang, Yong, et al.
Publicado: (2013)

The role of JAK-STAT signaling within the CNS
por: Nicolas, Celine S., et al.
Publicado: (2013)

Methotrexate Is a JAK/STAT Pathway Inhibitor
por: Thomas, Sally, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1vh2mvf4f0ndmrov0ofilvcs5o